inclusion criteria: 1. admitted to the hospital with symptoms of covid-19. 2. male and females age ≥18 years old. 3. confirmed positive sars-cov-2, through existing rt-pcr test within 7 days prior to randomization. 4. patients with clinical status categorized of scores 4, 5, or 6 on the covid-19 ordinal scale: * 4) hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (covid - 19 related or otherwise); * 5) hospitalized, requiring supplemental oxygen; * 6) hospitalized, on non-invasive ventilation or high flow oxygen devices; 5. participant able to swallow 4 capsules sequentially of the medication under investigation/ placebo 6. coagulation: inr ≤ 1.5 ×uln, and aptt ≤ 1.5×uln 7. women of child-bearing potential must have negative results of plasma pregnancy test (serum hcg). 8. participant (or legally authorized representative) gives written informed consent prior to performing any study procedures. 9. participant (or legally authorized representative) agree that participant will not participate in another covid-19 trial while participating in this study.

inclusion criteria: 1. admitted to the hospital with symptoms of covid-19. 2. male and females age ≥18 years old. 3. confirmed positive sars-cov-2, through existing rt-pcr test within 7 days prior to randomization. 4. patients with clinical status categorized of scores 4, 5, or 6 on the covid-19 ordinal scale: * 4) hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (covid - 19 related or otherwise); * 5) hospitalized, requiring supplemental oxygen; * 6) hospitalized, on non-invasive ventilation or high flow oxygen devices; 5. participant able to swallow 4 capsules sequentially of the medication under investigation/ placebo 6. coagulation: inr ≤ 1.5 ×uln, and aptt ≤ 1.5×uln 7. women of child-bearing potential must have negative results of plasma pregnancy test (serum hcg). 8. participant (or legally authorized representative) gives written informed consent prior to performing any study procedures. 9. participant (or legally authorized representative) agree that participant will not participate in another covid-19 trial while participating in this study.

inclusion criteria: admitted to the hospital with symptoms of covid-19. male and females age ≥18 years old. confirmed positive sars-cov-2, through existing rt-pcr test within 7 days prior to randomization. patients with clinical status categorized of scores 4, 5, or 6 on the covid-19 ordinal scale: 4) hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (covid - 19 related or otherwise); 5) hospitalized, requiring supplemental oxygen; 6) hospitalized, on non-invasive ventilation or high flow oxygen devices; participant able to swallow 4 capsules sequentially of the medication under investigation/ placebo coagulation: inr ≤ 1.5 ×uln, and aptt ≤ 1.5×uln women of child-bearing potential must have negative results of plasma pregnancy test (serum hcg). participant (or legally authorized representative) gives written informed consent prior to performing any study procedures. participant (or legally authorized representative) agree that participant will not participate in another covid-19 trial while participating in this study.

inclusion criteria: admitted to the hospital with symptoms of covid-19. male and females age ≥18 years old. confirmed positive sars-cov-2, through existing rt-pcr test within 7 days prior to randomization. patients with clinical status categorized of scores 4, 5, or 6 on the covid-19 ordinal scale: 4) hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (covid - 19 related or otherwise); 5) hospitalized, requiring supplemental oxygen; 6) hospitalized, on non-invasive ventilation or high flow oxygen devices; participant able to swallow 4 capsules sequentially of the medication under investigation/ placebo coagulation: inr ≤ 1.5 ×uln, and aptt ≤ 1.5×uln women of child-bearing potential must have negative results of plasma pregnancy test (serum hcg). participant (or legally authorized representative) gives written informed consent prior to performing any study procedures. participant (or legally authorized representative) agree that participant will not participate in another covid-19 trial while participating in this study.

inclusion criteria: 1. admitted to the hospital with symptoms of covid-19. 2. male and females age ≥18 years old. 3. confirmed positive sars-cov-2, through existing rt-pcr test within 7 days prior to randomization. 4. patients with clinical status categorized of scores 4, 5, or 6 on the covid-19 ordinal scale: - 4) hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (covid - 19 related or otherwise); - 5) hospitalized, requiring supplemental oxygen; - 6) hospitalized, on non-invasive ventilation or high flow oxygen devices; 5. participant able to swallow 4 capsules sequentially of the medication under investigation/ placebo 6. coagulation: inr ≤ 1.5 ×uln, and aptt ≤ 1.5×uln 7. women of child-bearing potential must have negative results of plasma pregnancy test (serum hcg). 8. participant (or legally authorized representative) gives written informed consent prior to performing any study procedures. 9. participant (or legally authorized representative) agree that participant will not participate in another covid-19 trial while participating in this study.

inclusion criteria: 1. admitted to the hospital with symptoms of covid-19. 2. male and females age ≥18 years old. 3. confirmed positive sars-cov-2, through existing rt-pcr test within 7 days prior to randomization. 4. patients with clinical status categorized of scores 4, 5, or 6 on the covid-19 ordinal scale: - 4) hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (covid - 19 related or otherwise); - 5) hospitalized, requiring supplemental oxygen; - 6) hospitalized, on non-invasive ventilation or high flow oxygen devices; 5. participant able to swallow 4 capsules sequentially of the medication under investigation/ placebo 6. coagulation: inr ≤ 1.5 ×uln, and aptt ≤ 1.5×uln 7. women of child-bearing potential must have negative results of plasma pregnancy test (serum hcg). 8. participant (or legally authorized representative) gives written informed consent prior to performing any study procedures. 9. participant (or legally authorized representative) agree that participant will not participate in another covid-19 trial while participating in this study.